Clinical trials: Idiopathic Inflammatory Myositis
Sporadic Inclusion Body Myositis
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
- Trial name
- NCT01423110
- Testing
- BYM338
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Polymyositis, Dermatomyositis
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM
Therapeutical trial in patients with idiopathic polymyositis (PM) and dermatomyositis (DM) is proposed. The study will investigate the safety and efficacy of combined methotrexate (MTX) + glucocorticoids (GC) treatment compared…
- Trial name
- Prometheus (NCT00651040)
- Testing
- Prednisone, Methotrexate
- Where
- Czechia
- Volunteers
- 31 people
- Sponsor
- Institute of Rheumatology, Prague
Dermatomyositis, Respiratory Injury
Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis
Dermatomyositis (DM) is a highly heterogeneous autoimmune disease characterized by rash and myasthenia. Beside these, respiratory involvement is one of the common complications of DM.
- Trial name
- CRAWFORD (NCT04747652)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis
- Trial name
- NCT07782450
- Testing
- PF-08154225
- Volunteers
- 54 people
- Sponsor
- Pfizer
Inflammatory Myopathies
Inspiratory Muscle Training in Patients With Inflammatory Myopathy
Inflammatory myopathies are rare autoimmune diseases leading to progressive muscle weakness, often including the respiratory muscles.
- Trial name
- NCT07274267
- Testing
- Inspiratory Muscle Training (IMT)
- Where
- Poland
- Volunteers
- 33 people
- Sponsor
- Józef Piłsudski University of Physical Education
Systemic Lupus Erythematosus, Sjogren's Syndrome
Cell Surface Marker Expression in Autoimmune Diseases
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's…
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis
- Trial name
- CASCADE (NCT03757065)
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Alpine Immune Sciences, Inc.
Fibrodysplasia Ossificans Progressiva (FOP)
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP.
- Trial name
- PIVOINE (NCT05027802)
- Testing
- Palovarotene
- Where
- 13 sites in United States, Argentina and 8 more
- Volunteers
- 61 people
- Sponsor
- Ipsen
Inflammatory Arthritis, Scleroderma
Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases
This study will assess the effect of a mindfulness meditation program administered via a smartphone application on health-related quality of life for patients with rheumatic disease.
- Conditions
- Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome
- Trial name
- NCT03937856
- Testing
- Calm- Mindfulness Meditation smartphone application
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Johns Hopkins University
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS)
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular…
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- in vivo CAR-T (NCT07413341)
- Testing
- TI-0032-III injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Myositis, Active Idiopathic Inflammatory Myopathy
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.
- Conditions
- Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA+ (NCT05979441)
- Testing
- Efgartigimod PH20 SC
- Where
- 92 sites in United States, Argentina and 27 more
- Volunteers
- 240 people
- Sponsor
- argenx
Rheumatic Diseases, Pediatric ALL
Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire
No tool has been found to evaluate behaviors that may hinder or facilitate physical activity in individuals with pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric ALL, Children, Only
- Trial name
- NCT06460766
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul University - Cerrahpasa
Systemic Sclerosis, Dermatomyositis
Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
Ectopic soft tissue calcifications or ossifications can complicate the course of numerous diseases; most of them are rare or very rare.
- Conditions
- Systemic Sclerosis, Dermatomyositis, iPPSD2
- Trial name
- ITS-PILOT (NCT03582800)
- Testing
- STS
- Where
- 11 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age.
- Trial name
- NCT00769860
- Testing
- Arimoclomol
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richard Barohn, MD
Juvenile Dermatomyositis
Juvenile Dermatomyositis
This is a retrospective descriptive cross-sectional and observational multicenter clinical and progressive study of juvenile dermatomyositis.
- Trial name
- NCT03433638
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
Idiopathic Inflammatory Myopathies, Physical Activity
Physical Training in Patients With Idiopathic Inflammatory Myopathies
Physical training may improve physical capacity and health parameters in various systemic autoimmune diseases, including idiopathic inflammatory myopathies.
- Trial name
- NCT03092167
- Testing
- Physical exercises
- Where
- Brazil
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Dermatomyositis, Dermatomyositis Sine Myositis
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD).
- Conditions
- Dermatomyositis, Dermatomyositis Sine Myositis, Dermatomyositis With Myopathy, Dermatomyositis With Respiratory Involvement
- Trial name
- NCT07486869
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Juvenile Dermatomyositis
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better…
- Trial name
- MYOCIT (NCT05524311)
- Testing
- Baricitinib, pharmacokinetics study, dosage of cytokines
- Where
- 13 sites in France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
The study aims to investigate the safety, tolerability, and preliminary clinical efficacy of BEN301 Injection in patients with autoimmune diseases.
- Conditions
- Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Sjogren's Syndrome (SS), Idiopathic Inflammatory Myopathies(IIM)
- Trial name
- NCT07527936
- Testing
- Single administration of 1x10^8 viable CD4+ CAR+ Foxp3+ cells., Single administration of 3x10^8 viable CD4+ CAR+ Foxp3+ cells.
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RenJi Hospital